Aim: Alpha2-Heremans Schmid glycoprotein (AHSG), also known as fetuin-A, is secreted from the liver and inhibits tyrosine kinase activity of the insulin receptor. Hyperglycemia in type 2 diabetes is not only a secondary manifestation of insulin resistance, but could also be responsible for directly inducing insulin resistance in target tissues. In this study, we examined the effect of high glucose ( 
. Sustained hyperglycemia activates the hexosamine biosynthesis pathway (HBP) 3, 4) and diacylglycerol (DAG)-protein kinase C (PKC) 5, 6) , and enhances oxidative stress 7, 8) . Interactions between these pathways induce insulin resistance, known as 'glucose toxicity'.
2-Heremans Schmid glycoprotein (AHSG), also known as fetuin-A, is an abundant plasma protein that is synthesized predominantly in the liver 9) . AHSG inhibits insulin receptor autophosphorylation, which is mediated by its intrinsic TK activity [10] [11] [12] . Acute administration of human recombinant AHSG inhibits insulin-stimulated tyrosine phosphorylation of the IR -subunit and IRS-1 in rat liver and skeletal muscle 12) . AHSG-null mice exhibit significantly enhanced insulin sensitivity and are resistant to weight gain on a high-fat diet
Introduction
Insulin mediates its actions through phosphorylation of the insulin receptor (IR), a transmembranespanning tyrosine kinase (TK) receptor. Binding of insulin to the IR leads to the activation of intrinsic tyrosine kinase, and subsequently to tyrosine phosphorylation of several substrates, such as insulin receptor substrate (IRS)1/IRS2 and Shc, which mediate the metabolic and mitogenic effects of insulin 1) . Hyperglycemia in type 2 diabetes is not only a secondary manifestation of insulin resistance, but may also be AHSG gene is located at chromosome 3q27, which has been identified as a susceptibility locus for type 2 diabetes and metabolic syndrome [15] [16] [17] . Recently, it has been shown that serum AHSG levels are significantly associated with insulin sensitivity in non-diabetic humans 18, 19) . These observations strongly supported the hypothesis that AHSG plays a physiological role in the regulation of insulin signaling and energy homeostasis.
If AHSG expression increases under hyperglycemic conditions, it could partly explain hyperglycemiainduced insulin resistance. Our study aimed to clarify the effects of high glucose (HG) concentrations on transcription of the AHSG gene, and its mechanisms in human hepatocyte cell lines.
Materials and Methods

Materials
Dulbecco's modified Eagle's medium (DMEM), penicillin, streptomycin, and fetal calf serum were obtained from Invitrogen (Carlsbad, CA), and all tissue culture plasticware was from Nunc (Roskilde, Denmark). Human insulin was kindly provided by Novo Nordisk A/S (Bagsvaerd, Denmark). The PKC inhibitors bisindolylmaleimide (BIM) and Ro-31-8220 were from Calbiochem (La Jolla, CA). Mitogenactivated protein kinase (MAPK)/extracellular signalregulated kinase (ERK) kinase (MEK) inhibitors PD98059 and U0126, and the phosphoinositide 3-kinase (PI3-K) inhibitor LY294002 were from Promega (Madison, WI). c-Jun N-terminal kinase (JNK) inhibitor SP600125, p38 inhibitor SB203580 and glucosamine were from Sigma (St. Louis, MO). 6-diazo-5-oxo-L-norleucine (DON) was from MP Biomedicals (Irvine, CA), and 4-hydroxy-2, 2, 6, 6-tetramethylpiperidine-1-oxyl (tempol), a stable spin trap for superoxide, was from Wako Pure Chemical Industries Ltd. (Osaka, Japan). Protein assay reagents were obtained from Bio-Rad (Hercules, CA), and nitrocellulose membrane from GE Healthcare (Buckinghamshire, UK). Polyclonal rabbit antibodies against human AHSG were from Santa Cruz Biotechnology (Santa Cruz, CA). Horseradish-peroxidase conjugated secondary antibodies were from MP Biomedicals (Irvine, CA).
Plasmid Constructs for Luciferase Assay
The genomic sample was obtained from the whole blood of one of the authors (T.S.). The genomic DNA sequence spanning the AHSG gene was obtained from GenBank accession numbers D67013 and AC068631 and the transcriptional start site was determined according to the AHSG mRNA sequence (accession number NM 001622). For the luciferase reporter gene assays, a DNA fragment of the 5'-flanking region of the AHSG gene ( 1091/ 22) was amplified by the nest-PCR method using the following sense and anti-sense primers (5'-AGATTTCTGC-CATCAGCCAC-3' and 5'-GCAAGACAAAGGAG-CAGGAC-3') for the first DNA fragment, and (5'-GGGGTACCGGTCTCCATGAGAGGGCTTC-3' and 5'-GAAGATCTCAGGCGTGCAGGTG-GTTG-3') for nest-PCR, respectively. Italic capitals show the synthetic linkers, and underlined capitals show restriction sites for both Kpn and Bgl . The DNA fragments were loaded onto an agarose gel for electrophoresis and then purified using a gel extraction kit (QIAquick Gel Extraction Kit; QIAGEN GmbH, Hilden, Germany). The purified DNA fragments were digested enzymatically (Toyobo, Tokyo, Japan) and inserted into a firefly luciferase expression vector, pGL4.12 [luc2CP] vector (Promega), which had already been digested enzymatically. The plasmid construct, pGL4-Fetu(A) ( 1091/ 22), was subcloned into JM109 bacterial cells, which was followed by isolation with a plasmid purification kit (QIAGEN Plasmid Midi Kit; QIAGEN GmbH). Sequences of the introduced DNA fragments were confirmed using a cycle sequencing method and an analyzer (BigDye Terminator Cycle Sequencing FS Ready Reaction Kit and ABI PRISM TM 310 Genetic Analyzer), using the primers described for pGL4.12 and specific oligonucleotides within the inserted DNA sequence. The DNA insert sequence had adenine at position 799. For deletion analysis, various lengths of plasmids including 477/ 22, 302/ 22, 196/ 22, and 89/ 22 were generated using the same antisense and sense primers 5'-GGGGTACCGGCCTTGTT-CTCCCTGTAGG-3', 5'-GGGGTACCGTCCA-CCTCATTCCCTCAGC-3', 5'-GGGGTACCGG-GACCAGGCGATGTCCTAAC-3', and 5'-GGGG-TACCTTCTTCCGGCAGGCTCCAAC-3', respectively. DNA fragments were inserted into the firefly luciferase expression vector, pGL4.12 (Promega), and subcloned into JM109 bacterial cells. DNA fragments were confirmed by the cycle sequencing method.
Cell Culture, Transfection, Treatment and Reporter Gene Assay
Since transcription of the AHSG gene takes place predominantly in the liver, we used HepG2 cells, a human hepatoma cell line, in this study. The cells were cultured and maintained in DMEM supplemented with 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin, and 20 g/mL streptomycin.
Cultures were maintained at 37 in a humidified 5% CO2-containing atmosphere.
For transient transfection experiments, HepG2 cells, plated in 24-well plates, were transfected with the test plasmids and Tfx TM -20 transfection reagents (Promega). The pRL-TK vector, which expressed Renilla luciferase (Promega), was co-transfected as an internal control. The final transfected DNA amount in each well was adjusted by the addition of empty vectors. Twenty-four hours after the start of transfection, the culture medium was replaced with serumfree and glucose-free medium, and the cells were then treated with the test substances for a defined time period. The final concentrations of reagents were 20 M for DON, PD98059, U0126, SP600125 and SB203580, 5 M for BIM, 1 mM for Ro-31-8220, 1 mM for tempol and 2 or 4 M for glucosamine. When both D-glucose and the inhibitors were used, the cells were pretreated with the inhibitors and Dglucose was added 60 min later, and incubated for 24 h. When we examined the effects of insulin treatment on promoter activity, the cells were made quiescent by serum starvation for 24 h after transfection. At that time, insulin was added at 1 − 100 nM, and the cells were lysed after an additional incubation period. Both firefly and Renilla luciferase activities were measured using the Dual-Luciferase ® Reporter Assay System (Promega).
Gel Electrophoresis and Western Blot Analysis
The cells were lysed in 300 L buffer (20 mM Tris acetate, pH 7.0, 0.27 M sucrose, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 1 mM PMSF, 10 mM benzamidin and 5 g/ L leupeptin) per 3.5 cm dish. Supernatants were obtained by centrifugation at 15,000 rpm for 10 minutes at 4 . The protein concentration was normalized, and 10 g protein per sample was separated by SDS-PAGE. The proteins were then transferred to a nitrocellulose membrane, which had been blocked in 1 PBS buffer containing 0.2% Tween 20 (PBS-Tween buffer) and 3% milk powder, and subsequently in 1 PBS-Tween buffer containing 0.2% gelatin, prior to overnight incubation with polyclonal antibodies for human AHSG. Immunoreactive proteins were visualized using horseradish peroxidase-coupled secondary antibodies and enhanced chemiluminescence (ECL TM ) reagents.
Statistical Analyses
Each experiment was repeated at least three times to confirm the results. Results of the reporter gene assay are presented as the means S.E.M. For statistical analyses, data were compared by one-way ANOVA with Fisher's protected least significant difference test. P values less than 0.05 were considered significant. Since it was unclear how D-glucose affects the AHSG promoter, we used F1 in later experiments, as it had the longest sequence of the fragments that showed significant promoter activity. The reporter gene assay was performed in HepG2 cells using pGL4-Basic vectors containing various lengths of the AHSG promoter region. Cells were seeded into 24-well dishes and were transiently transfected with pGL4-Basic containing the AHSG promoter region and co-transfected with pRL-TK as an internal control. The cells were harvested 24 h after the start of transfection, and both firefly and Renilla luciferase activities were assayed. AHSG promoter activity is expressed as firefly luciferase activity/ Renilla luciferase activity. Mean promoter activity of the 1091/ 22 fragment is set as 100, and activities relative to the 1091/ 22 fragment are presented. Data represent the means S.E.M. (n 8). p 0.0001
Results
Deletion Analysis of Upstream
Effects of Glucose on AHSG Promoter Activity
To examine the effects of D-glucose on AHSG transcription, HepG2 cells were treated with 5 − 30 mM D-glucose. As shown in Fig. 2 , D-glucose dosedependently enhanced AHSG promoter activity. Although the dose-dependent effect and the fold induction of promoter activity by D-glucose varied depending on the cell condition, treatment with 25 − 30 mM D-glucose was found to produce more reproducible results than concentrations of 20 mM or less, and there was no significant difference in promoter activation between 25 and 30 mM D-glucose in repeated experiments. In a time-course study using 25 mM D-glucose, the highest promoter activity was observed when cells were incubated for 12 h, but there was no significant difference in promoter activity between incubation for 12 and 48 h (Fig. 3) ; therefore, in later experiments, we treated cells with 25 mM D-glucose for 24 h. Although fructose had a similar stimulatory effect on AHSG promoter activity, L-glucose and mannitol had no effect on AHSG promoter activity (Fig. 4) .
Effects of HG on AHSG Protein Expression
To investigate whether HG-induced transactivation leads to the enhancement of AHSG protein expression, we carried out Western blot analysis and found that HG (25 mM, 24 h) significantly enhanced AHSG protein expression (Fig. 5) .
Effects of Insulin on AHSG Promoter Activity
We also investigated the effects of insulin on promoter activity. Following serum starvation for 24 h, cells were treated with 1 − 100 nM insulin for 1 − 24 h. Insulin showed no significant effect on AHSG promoter activity at any concentration or incubation period. No additive effect was detected when cells were treated with a combination of HG and insulin (data not shown).
Mechanisms of HG-Induced AHSG Promoter Activation
Hyperglycemia activates the DAG-PKC pathway 20, 21) and enhances oxidative stress, and they are closely connected. We therefore tested the effects of PKC inhibitors BIM and Ro-31-8220, and the radical scavenger tempol (Fig. 6) on AHSG promoter activation. BIM (5 M) had no effects on basal or HGinduced promoter activity. Ro-31-8220 (1 mM) and tempol (1 mM) reduced both basal and HG-induced promoter activity, but did not reduce fold induction by HG; changes in fold induction by Ro-31-8220 and tempol were 2.4 to 2.9-fold and 2.7 to 3.9-fold, respectively. Since hyperglycemia also activates HBP, we next examined the effect of DON, an inhibitor of glutamine: fructose-6-phosphate amidotransferase, which is a rate-limiting enzyme of HBP. The result showed no effect of 20 M DON on HG-induced promoter activity (Fig. 7, left) . In accordance with this, treat- ment with glucosamine showed no effect on basal promoter activity (Fig. 7, right) . Finally, the possible involvement of the MAPK signaling pathway in HG-induced AHSG promoter activation was tested (Fig. 8) . MEK inhibitors PD98059 (20 M) and U0126 (20 M) significantly inhibited the fold induction by HG; changes in fold induction by PD98059 and U0126 were 9.3 to 2.7-fold and 7.6 to 3.9-fold, respectively. Although the p38 inhibitor SB203580 (20 M) reduced both basal and HGinduced promoter activity, it had no effect on fold induction (8.1-to 7.9-fold). The JNK inhibitor SP600125 (20 M) elicited increased fold induction by HG (8.0-fold to 10.4-fold), while the PI3-K inhibitor LY294002 (20 M) had no effect on fold induction by HG (data not shown).
To identify which region in the AHSG upstream sequence is crucial for the promoter activation by HG, we then compared the promoter activation in response to HG between F1 ( 1091/ 22), F2 ( 477/ 22), and F3 ( 302/ 22), all of which showed significant luciferase activity; however, no differences in both the fold induction of promoter activity by HG and the inhibitory effect of PD98059 were detected between fragments (Fig. 9) .
Discussion
In this study, we demonstrated that D-glucose dose-dependently enhanced the transcriptional activity of the AHSG gene. Furthermore, we confirmed that, using Western blot analysis, this transactivation by HG leads to increased AHSG protein expression in HepG2 cells. Since L-glucose and mannitol had no effect on AHSG promoter activity, the effect of Dglucose on promoter activity was considered to be through its metabolic actions. Since hyperglycemia activates HBP 3, 4) and the DAG-PKC pathway 5, 6) , and enhances oxidative stress 7, 8) , we tested the effects of inhibitors of these pathways and a radical scavenger; however, we found that none of them affected HG-induced promoter activation.
We next tested the possibility that the MAPK signaling pathway, which is also associated with the glucose-stimulated intracellular signaling cascade, is involved in HG-induced promoter activation. MAPKs are a family of serine/threonine kinases that play an essential role in signal transduction by modulating gene transcription in the nucleus in response to changes in the cellular environment. MAPKs control key cellular functions, including proliferation, differentiation, migration and apoptosis. They include ERK1/2, JNK, and p38s, and each can be stimulated by a separate protein kinase cascade that includes the sequential activation of a specific MAPK kinase kinase and a MAPK kinase, which in turn phosphorylates and activates their downstream MAPKs. We found that MAPK/ERK kinase (MEK) inhibitors, but not p38 or JNK inhibitors, significantly inhibited HGinduced promoter activation. These results indicate that HG induces transactivation of the AHSG gene, at least in part, through the ERK1/2 signaling pathway; however, it remains unclear why insulin showed no effect on AHSG promoter activity, despite its wellknown effect on the MAPK signaling pathway.
In deletion analysis, as the length of the promoter sequence shortened, luciferase activity increased, and F3 ( 302/ 22) showed the highest promoter activity, suggesting a repressive sequence upstream of this promoter region. On the other hand, F4 ( 196/ 22) and F5 ( 89/ 22) showed markedly decreased luciferase activity. This result indicates that an enhancer sequence is located between positions 302 and 196, which is consistent with a previous report by Banine et al. 22) ; however, no difference in the fold induction of promoter activity by HG was detected between F1, F2 and F3, all of which had significant luciferase activity, suggesting that the sequence crucial for HG-induced promoter activation is located down- stream of position 302. In this study, we could not identify the promoter sequence crucial for HG-induced promoter activation, since we could not form an accurate estimate of HG-induced activation because of extremely reduced promoter activity of F4 ( 196/ 22) and F5 ( 89/ 22). Computer analysis using TRANSFAC revealed that this region contains several putative binding sequences for transcription factors, which are known to be regulated by ERK1/2, including Elk-1, serum responsive factor, and c-Myc 20, 21) ; therefore, further work is required to clarify which element is crucial for activation.
Despite the accumulating data regarding an association between AHSG and insulin resistance both in animals [12] [13] [14] and humans 18, 19) , it remains unclear whether the serum concentration of AHSG is increased in diabetic patients. Ix et al. 23) reported that an increased serum AHSG level was significantly associated with a high prevalence of diabetes mellitus. On the other hand, Mori et al. 19) reported no difference in mean serum AHSG levels between non-diabetic and type 2 diabetic subjects. Transcriptional regulation in diabetes in vivo may be complex, since factors other than hyperglycemia (e.g. hyper/hypoinsulinemia and inflammation) could also influence AHSG gene transcription. In fact, it has been reported that interleukin-6, interleukin-1 24) and tumor necrosis factor- 25) downregulate AHSG synthesis. In addition, we did not examine the chronic effect of high glucose concentrations on AHSG transcription/expression, which may be different from the short-term effect.
Interestingly, fructose showed a similar enhancing effect on AHSG promoter activity (Fig. 4) . We also found that this was a dose-dependent effect (data not shown). Fructose has detrimental effects on lipid metabolism and causes hepatic insulin resistance 26, 27) and increased serum fructose levels have been shown in diabetic patients 28) ; therefore, we should also inves- 
Conclusion
We demonstrated for the first time that HG induces transactivation of the AHSG gene through the ERK1/2 signaling pathway in cultured hepatoma cells. Increased hepatic AHSG expression may partly explain glucose toxicity in diabetes. -+ *** *** *** Fig. 9 
